Ani pharmaceuticals reports q1 2020 results and appoints interim ceo

Ani pharmaceuticals reports first quarter 2020 results and appoints interim ceo.q1 adjusted non-gaap earnings per share $1.04.q1 gaap loss per share $0.59.q1 revenue $49.8 million versus refinitiv ibes estimate of $50.2 million.q1 earnings per share estimate $0.89 -- refinitiv ibes data.appoints patrick d. walsh interim president and ceo.suspends guidance for 2020.is currently conducting search for a president and ceo.
ANIP Ratings Summary
ANIP Quant Ranking